Journal
CURRENT OPINION IN BIOTECHNOLOGY
Volume 65, Issue -, Pages 52-59Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.copbio.2019.12.014
Keywords
-
Funding
- Swiss National Science Foundation [310030_182384]
- Swiss National Science Foundation (SNF) [310030_182384] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Among immune correlates of clinical responses, tumor-specific neoantigens took the spotlight as relevant targets for cancer immunotherapy. The implementation of pipelines for personalized cancer therapy remains challenging due to the privacy, that is patient-specificity, of neoantigens and the low-frequency of neoantigen-specific T cells in blood and tumor samples. To overcome these obstacles, recent developments in the field of biotechnology have allowed the multiplexed identification of neoepitope-specific T cells. This review addresses the pros and cons of conventional neoantigen screening methodologies and highlights the current as well as the prospective biotechnological opportunities in the field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available